类风湿关节炎临床缓解期延长皮下托珠单抗给药间隔的随机开放标签试验
该研究纳入对csDMARDs或生物制剂应答不佳的活动性RA患者,先接受TCZ-SC 162mg每周一次治疗24周,达到临床缓解者随机继续每周一次或改为每2周一次治疗24周。第48周时,每周一次组维持缓解比例显著高于每2周一次组(90% vs 73%,P=0.004),但多数患者减半剂量仍可维持缓解,安全性相似。
要点
- TCZ-SC 162mg每周一次治疗24周后,45%(179/401)患者达到临床缓解并随机分组。
- 延长给药间隔至每2周一次者第48周维持缓解率低于每周一次组(73% vs 90%,P=0.004)。
- 两组安全性和耐受性相似,减半剂量策略值得进一步研究。
核心结论
- 在RA临床缓解患者中,将TCZ-SC给药间隔从每周一次延长至每2周一次与24周后维持缓解的可能性降低相关,且未带来更好的耐受性。
- 尽管延长间隔组维持缓解率较低,但多数患者仍能以半剂量维持缓解,该策略值得进一步研究。
研究设计与样本
- 随机、开放标签试验:活动性RA患者先进入单臂治疗期,接受TCZ-SC 162mg每周一次(单药或联合csDMARD)治疗24周。
- 第20和24周达到临床缓解(DAS28<2.6)的患者随机分为继续每周一次组(n=89)或改为每2周一次组(n=90),治疗24周。
主要发现
- 单臂治疗期401例患者中179例(45%)达到临床缓解并随机分组。
- 第48周时,每周一次组维持临床缓解的比例显著高于每2周一次组(90% vs 73%,P=0.004)。
- 第48周DAS28评分较基线平均变化:每周一次组-4.07分(SD 1.29),每2周一次组-3.65分(SD 1.35),P=0.034。
- 其他疗效指标在两组间无显著差异,安全性和耐受性参数相似。
关键数值与推荐
- 临床缓解定义为DAS28<2.6。
- TCZ-SC剂量为162mg,每周一次或每2周一次。
临床怎么用
- 对于达到临床缓解的RA患者,延长TCZ-SC给药间隔至每2周一次可能降低维持缓解的概率,需谨慎评估。
- 部分患者减半剂量仍可维持缓解,提示可在密切监测下考虑个体化减量策略。
局限性
- 开放标签设计可能引入偏倚。
- 研究未报告盲法、样本量计算或长期随访数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the efficacy and safety of increasing the dose interval of subcutaneous tocilizumab (TCZ-SC) in patients with rheumatoid arthritis (RA) who are in clinical remission. METHODS: RA patients with active disease and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) or to a biologic agent were entered into a single-arm treatment phase with 162 mg of TCZ-SC administered once weekly (TCZ-SC 162 mg qw) as monotherapy or in combination with a csDMARD for 24 weeks. Patients who achieved clinical remission at weeks 20 and 24 were randomized to continue with the same regimen or to switch to 162 mg TCZ-SC administered every 2 weeks (TCZ-SC 162 mg q2w) for 24 weeks (open-label). Patients with a Disease Activity Score in 28 joints (DAS28) of <2.6 were considered to be in clinical remission. RESULTS: In total, 179 (45%) of 401 patients in the single-arm phase achieved clinical remission and were randomized to continue to receive TCZ-SC 162 mg qw (n = 89) or to switch to TCZ-SC 162 mg q2w (n = 90) for 24 weeks. At week 48, significantly more patients treated with TCZ-SC 162 mg qw remained in clinical remission compared to patients who received TCZ-SC 162 mg q2w (90% versus 73%; P = 0.004). The results of other efficacy measures revealed greater efficacy with TCZ-SC 162 mg qw, but none of the efficacy outcomes in this group were significantly different from those in patients treated with TCZ-SC 162 mg q2w, except for the mean change from baseline in the DAS28 score at week 48 (mean change -4.07 points [SD 1.29] versus -3.65 points [SD 1.35]; P = 0.034). Tolerability and safety parameters were similar between the treatment groups. CONCLUSION: Increasing the dose interval of TCZ-SC in patients with RA was associated with a lower likelihood of maintaining remission after 24 weeks and was not associated with better tolerability. However, most patients were able to sustain remission with a half-dose of TCZ-SC, and therefore this strategy deserves further investigation.
引用
- Sanmarti R, Veale DJ, Martin-Mola E, et al. Reducing or Maintaining the Dose of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis in Clinical Remission: A Randomized, Open-Label Trial. Arthritis Rheumatol. 2019. PMID: 31087542. doi:10.1002/art.40905
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。